SFV Replicon Particle Purification Using Sequential Ion Exchange
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing methods for large-scale purification of Semliki Forest Virus (SFV) replicon particles are not cost- and time-effective, limiting their commercial application in vaccines and gene therapies.
Innovation Solution
A two-step chromatographic process involving a strong anion exchange column followed by a cation exchange resin, using a zwitterionic buffer, is employed to purify SFV replicon particles, with stabilization using human serum albumin (HSA) for long-term storage.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If traditional large-scale purification methods are used, then purification capacity is sufficient, but cost-effectiveness and time-efficiency deteriorate
Solution Approach 1:
The purification process is divided into multiple sequential chromatographic steps (anion exchange, cation exchange, size exclusion) that can be performed in a modular fashion. Each step targets specific impurities, allowing the process to be optimized and scaled independently for each purification stage, improving overall cost-effectiveness while maintaining high purification capacity.
Solution Approach 2:
The invention utilizes changes in buffer conditions (pH, ionic strength, conductivity) to selectively bind and elute viral particles at different stages. By optimizing these parameters for each chromatographic step, the process achieves high purification efficiency with reduced material consumption and shorter processing times, addressing both productivity and cost-effectiveness.
2Productivity
If traditional large-scale purification methods are used, then purification capacity is sufficient, but processing time increases
Solution Approach 1:
Clarification steps and endonuclease treatment are performed before chromatographic purification to pre-remove major impurities. This preliminary action reduces the burden on subsequent purification steps, allowing them to proceed more quickly and efficiently, thereby reducing overall processing time while maintaining high purification capacity.
Solution Approach 2:
The chromatographic steps are designed to be performed in continuous sequence without interruption, with buffer conditions optimized for seamless transition between stages. This continuous processing approach eliminates idle time between steps and maximizes throughput, addressing the time-efficiency concern while maintaining high purification capacity.
3Manufacturing precision
If purification steps are increased to improve purity, then purity of SFV particles is improved, but process complexity increases
Solution Approach 1:
Each chromatographic resin and buffer system is designed to perform multiple functions: removing specific classes of impurities, concentrating viral particles, and preparing the sample for the next step. This multi-functionality reduces the need for additional specialized steps, achieving high purity while limiting the increase in process complexity.
Solution Approach 2:
The invention achieves high purity by systematically varying buffer parameters (pH, ionic strength, conductivity) across different chromatographic steps rather than adding numerous physical separation steps. This approach maintains relatively simple equipment requirements while achieving excellent purification results, balancing purity with process complexity.
4Duration of action of stationary object
If storage stability is improved for long-term storage, then storage duration is extended, but additional stabilization steps are required
Solution Approach 1:
Stabilizing agents and protective buffers are introduced as intermediary substances that mediate between the viral particles and the storage environment. These intermediaries prevent degradation without requiring complex stabilization procedures, extending storage duration while maintaining relatively simple processing.
Solution Approach 2:
The final buffer composition is optimized with specific pH, ionic strength, and protective agents to create a storage environment that inherently stabilizes viral particles for long-term storage. This parameter optimization achieves extended storage stability through a single formulated buffer system rather than multiple additional stabilization steps, balancing storage duration with process simplicity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This method allows for high-yield, large-scale purification of highly purified SFV replicon particles with stable storage up to 2 years, suitable for human and veterinary medicine, maintaining viral titer and reducing impurities.
Implementation Method 1
contacting the preparation obtained in step (iii) with a strong anion exchange resin under conditions and for a time sufficient to bind to said resin
Implementation Method 2
contacting the preparation obtained in step (vi) with a strong cation exchange resin under conditions and for a time sufficient to bind to said resin
Data Source
Figure 1
Figure 2A
Figure 2B
AI summary
The invention relates to purified vaccine preparations and methods for providing them. Provided is a method for providing purified viral particles of SFV, comprising the steps of i) providing a preparation of SFV replicon particles; ii) subjecting said preparation to an endonuclease treatment under conditions allowing for degradation of exogenous/host cell DNA and RNA; iii) bringing said endonuclease-treated preparation with a zwitterionic buffer solution to a conductivity of up to about 5.5 mS/cm; iv) contacting the preparation obtained in step (iii) with a strong anion exchange resin; v) eluting the bound SFV replicon particles from said anion exchange resin; vi) bringing the eluted SFV particles to a conductivity in the range of 7.0 to 9.0 mS/cm; vii) contacting the preparation obtained in step (vi) with a strong cation exchange resin under conditions and for a time sufficient to bind to said resin; viii) eluting the bound SFV replicon particles from said cation exchange resin with a zwitterionic buffer solution and collecting at least one fraction containing purified SFV replicon particles; and ix) stabilizing the at least one purified fraction by adding human serum albumin (HSA) to a final concentration in the range of about 0.5 - 2 w/v%, preferably about 1 w/v%.